Man Group plc Invests $5.47 Million in Moderna, Inc. $MRNA

Man Group plc bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 78,168 shares of the company’s stock, valued at approximately $5,474,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new position in Moderna during the second quarter valued at $2,142,877,000. Capital World Investors purchased a new position in shares of Moderna in the fourth quarter worth about $378,299,000. Theleme Partners LLP purchased a new position in Moderna during the second quarter worth approximately $564,272,000. Alyeska Investment Group L.P. acquired a new position in Moderna in the 4th quarter valued at about $95,209,000. Finally, Norges Bank purchased a new stake in Moderna in the fourth quarter valued at $79,707,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Bank of America upgraded Moderna from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 19th. William Blair started coverage on Moderna in a research note on Friday. They issued an “outperform” rating on the stock. The Goldman Sachs Group upped their target price on Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, August 19th. Finally, UBS Group boosted their target price on shares of Moderna from $50.00 to $150.00 and gave the company a “neutral” rating in a research note on Thursday, August 20th. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $80.53.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is owned by insiders.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Moderna Price Performance

Shares of MRNA opened at $137.99 on Friday. The stock has a fifty day moving average price of $77.11 and a 200 day moving average price of $59.73. The company has a market cap of $55.09 billion, a P/E ratio of -17.27 and a beta of 0.91. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.13) earnings per share. On average, research analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.